Bharat Biotech`s Covaxin gets DGCI nod to conduct clinical trials on children above 2 years
The national drug regulator said that it has accepted the recommendation of the SEC “after careful examination” and accorded permission to Covaxin manufacturer Bharat Biotech.
ليست هناك تعليقات:
إرسال تعليق